Premium
Phase II trial of 5‐fluorouracil, leucovorin, interferon‐α‐2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma
Author(s) -
Temeck Barbara K.,
Liebmann James E.,
Theodossiou Christopher,
Steinberg Seth M.,
Cook John A.,
Metz David C.,
Shawker Thomas H.,
Allegra Carmen J.,
Russo Angelo,
Pass Harvey I.
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960615)77:12<2432::aid-cncr3>3.0.co;2-o
Subject(s) - medicine , fluorouracil , chemotherapy , oncology , cisplatin , neoadjuvant therapy , carcinoma , phases of clinical research , cancer , breast cancer
BACKGROUND Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5‐fluorouracil (5‐FU), leucovorin, interferon‐α‐2a, and ciplastin to 11 patients with locally advanced disease. METHODS Eleven patients with squamous cell or adenocarcinoma of the esophagus were treated preoperatively with two to three cycles of combination chemotherapy. Nine patients underwent resection with curative intent. RESULTS Six patients received three cycles of chemotherapy, and five received two. Dose reduction was necessary for two patients. One patient achieved a pathologic complete response, histologically confirmed. Of the eleven patients, two did not undergo surgery because of progressive disease during chemotherapy. Seven of the 9 patients relapsed after surgery and 2 have been disease free for 27 months. CONCLUSIONS The combination 5‐FU, leucovorin, interferon‐α‐2a, and cisplatin administered in a neoadjuvant setting resulted in a median survival of 11.8 months with a median time to relapse of 7 months. Cancer 1996;77:2432‐9.